Top Biotech Companies in Singapore (91)
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug...
We are a bunch of highly experienced doctors, technologists, insurance experts and managed care practitioners who believe that we can use technology to improve the quality of Asian healthcare while lowering costs. We also know what works in Asia, and we brought best-in-class technologies from around the world on to one platform to make that belief a reality. We get...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element. Mice, test tubes, and other conventional preclinical models don't truly represent the complexities of...
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery...
ChemLex is a Singapore-based company delivering autonomous chemical synthesis services for the pharmaceutical and biotech industry. Our AI-integrated autonomous synthesis platform improves quality, consistency, and productivity while reducing costs and supporting ESG goals.
10,000 people, one global focus - enhancing the health and well-being of pets, people, and livestock. We are passionate about what we do at IDEXX – and why wouldn’t we be? When you’re working to raise the standard of care for pets, make drinking water safe for billions and keep our livestock population around the globe healthy and free of...
IDEXX's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show double‑digit top‑line increases in 2025 and early 2026, with Q1 and Q2 2026 up 14% and 10% reported, respectively, and full‑year 2026 revenue guidance raised. Growth is broad‑based across Companion Animal Group diagnostics, Water, and LPD.
Profitability: Margin expansion is attributed to recurring diagnostics volume, pricing, and productivity, translating into higher EPS and operating leverage. Guidance and quarterly updates highlight continued earnings growth if these drivers are maintained.
Strong Market Position & Advantage: The company is widely regarded as the category leader in companion‑animal diagnostics, reinforced by an integrated ecosystem of instruments, consumables, labs, imaging, and software. Independent analyses consistently place it at or near the top across key diagnostics segments, supporting durable advantage.
AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications:...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
Trinity Life Sciences is a modern partner to companies in the life sciences industry with nearly 30 years of expertise. The firm combines strategy, insights, and analytics to help life science executives with clinical and commercial decision-making. Serving over 300 pharmaceutical, biotech, and medical device clients, Trinity helps them develop the right drugs and devices for today’s market and optimize...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers...
Kyberlife's technology arm holds the first open marketplace in Asia with an easy-to-use platform that hosts healthcare vendors, life-science companies & manufacturers globally. Kyberlife also has a distribution arm that facilitates licensed distribution of life-science/pharmaceutical/medical products, Instruments, equipment to the SEA region. Our vision is to provide for the millions of researchers in Asia, SEA & Australasia to shop for...
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to...
QIAGEN's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leadership in latent TB blood testing (QuantiFERON) and entrenched sample‑preparation technologies is reinforced by global guidelines and deep workflow stickiness. The company is also building share in digital PCR and competes credibly in syndromic panels despite strong incumbents.
Resilient & Sustainable Growth: Net sales grew in 2025 with guidance for further mid‑single‑digit growth in 2026, and earnings are guided to improve. Growth is increasingly driven by non‑COVID ‘pillars’ with recurring consumables and software that generally support steadier demand.
Future-Ready Strategy: Management pruned non‑core lines (e.g., NeuMoDx exit) and refocused investment on five growth pillars with multi‑year targets through 2028. Ongoing menu expansions, regulatory submissions, and targeted M&A (e.g., single‑cell and clinical genomics software) indicate continued positioning for scaled, profitable growth.
Biomed Global is a leading total solution provider in the biomedical and life sciences industry, operating across Southeast Asia. The company provides a holistic range of innovative medical solutions and cutting-edge biomedical technologies spanning research, development, and clinical applications. Its mission is to advance healthcare standards and facilitate medical breakthroughs by bringing together leading-edge medical solutions and expert support to...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies,...
